JP7311583B2 - Ｇａｂａ受容体モジュレーターとしてのジフルオロメチル－フェニルトリアゾール - Google Patents

Ｇａｂａ受容体モジュレーターとしてのジフルオロメチル－フェニルトリアゾール Download PDF

Info

Publication number
JP7311583B2
JP7311583B2 JP2021503007A JP2021503007A JP7311583B2 JP 7311583 B2 JP7311583 B2 JP 7311583B2 JP 2021503007 A JP2021503007 A JP 2021503007A JP 2021503007 A JP2021503007 A JP 2021503007A JP 7311583 B2 JP7311583 B2 JP 7311583B2
Authority
JP
Japan
Prior art keywords
alkyl
pain
group
disorder
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021503007A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531291A (ja
JP2021531291A5 (enExample
Inventor
ヤーヌス・シュライバー・ラーセン
フロリアン・ビンダー
ユンハイ・ツイ
オリヴァー・フッケ
ラドスワフ・リピンスキー
フロリアン・モンテル
マルクス・オスターマイアー
アレクサンドル・ペレラ
シュテファン・ペータース
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2021531291A publication Critical patent/JP2021531291A/ja
Publication of JP2021531291A5 publication Critical patent/JP2021531291A5/ja
Application granted granted Critical
Publication of JP7311583B2 publication Critical patent/JP7311583B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021503007A 2018-07-20 2019-07-19 Ｇａｂａ受容体モジュレーターとしてのジフルオロメチル－フェニルトリアゾール Active JP7311583B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18184716 2018-07-20
EP18184716.1 2018-07-20
PCT/EP2019/069593 WO2020016443A1 (en) 2018-07-20 2019-07-19 Difluoromethyl-phenyl triazoles as gaba receptor modulators

Publications (3)

Publication Number Publication Date
JP2021531291A JP2021531291A (ja) 2021-11-18
JP2021531291A5 JP2021531291A5 (enExample) 2022-07-27
JP7311583B2 true JP7311583B2 (ja) 2023-07-19

Family

ID=63014393

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021503007A Active JP7311583B2 (ja) 2018-07-20 2019-07-19 Ｇａｂａ受容体モジュレーターとしてのジフルオロメチル－フェニルトリアゾール

Country Status (8)

Country Link
US (2) US10941137B2 (enExample)
EP (1) EP3823967B1 (enExample)
JP (1) JP7311583B2 (enExample)
CN (1) CN112424197B (enExample)
AR (1) AR117615A1 (enExample)
BR (1) BR102019014802A2 (enExample)
TW (1) TW202019915A (enExample)
WO (1) WO2020016443A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12649738B2 (en) 2020-03-26 2026-06-09 Richter Gedeon Nyrt. 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine derivatives as GABAA α5 receptor modulators
TWI901650B (zh) * 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔３，４－ｃ〕嗒衍生物
EP4149933B1 (en) * 2020-05-13 2024-06-12 F. Hoffmann-La Roche AG New triazolyl derivatives as gaba a alpha5 pam
EP3971179A1 (en) * 2020-09-22 2022-03-23 Boehringer Ingelheim International GmbH Difluoromethyl-pyridin-2-yl triazoles
TWI915398B (zh) * 2020-08-05 2026-02-21 丹麥商薩尼奧納有限責任公司 二氟甲基-吡啶-2-基三唑
EP3992188A1 (en) * 2020-10-29 2022-05-04 Boehringer Ingelheim International GmbH Difluoromethyl-pyridin-2-yl triazoles
EP3950683A1 (en) * 2020-08-05 2022-02-09 Boehringer Ingelheim International GmbH Difluoromethyl-pyridin-2-yl triazoles
IL310708A (en) * 2021-08-12 2024-04-01 Shanghai Simr Biotechnology Co Ltd The history of converted triazole, a method for its preparation, its pharmaceutical preparation and its use
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
CN116462664B (zh) * 2022-03-08 2025-07-01 上海赛默罗生物科技有限公司 吡唑环类化合物、其制备方法、组合物及应用
CN116854680A (zh) * 2022-03-28 2023-10-10 上海赛默罗生物科技有限公司 异噁唑-杂环类衍生物、药物组合物和用途
WO2024251133A1 (zh) * 2023-06-05 2024-12-12 武汉人福创新药物研发中心有限公司 作为α5-GABAA受体调节剂的杂环化合物及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011505402A (ja) 2007-12-04 2011-02-24 エフ．ホフマン−ラ ロシュ アーゲー イソオキサゾロ−ピリダジン誘導体
JP2013543852A (ja) 2010-11-09 2013-12-09 エフ．ホフマン−ラ ロシュ アーゲー トリアゾール誘導体及びその神経障害に対する使用
WO2014001278A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001280A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
JP2015521643A (ja) 2012-06-26 2015-07-30 サニオナ・エイピイエス フェニルトリアゾール誘導体及びｇａｂａａ受容体複合体を調節するための該フェニルトリアゾール誘導体の使用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009508905A (ja) 2005-09-19 2009-03-05 エフ．ホフマン−ラ ロシュ アーゲー ＧＡＢＡＡα５逆アゴニストとしてのイソオキサゾロ誘導体
CN101277952B (zh) 2005-10-11 2011-09-28 弗·哈夫曼-拉罗切有限公司 异*唑衍生物
DE602006014185D1 (de) 2005-11-09 2010-06-17 Hoffmann La Roche 3-arylisoxazol-4-carbonylbenzofuranderivative
RU2426731C2 (ru) 2005-12-23 2011-08-20 Ф. Хоффманн-Ля Рош Аг Производные арил-изоксазоло-4-ил-оксадиазола
PL1968973T3 (pl) 2005-12-27 2012-03-30 Hoffmann La Roche Pochodne aryloizoksazol-4-iloimidazolu
ATE537171T1 (de) 2005-12-27 2011-12-15 Hoffmann La Roche Aryl-isoxazol-4-yl-imidazoä1,5-aüpyridin-deriva e
ES2340221T3 (es) 2006-05-24 2010-05-31 Eli Lilly And Company Compuestos y procedimientos para modular fxr.
KR101119365B1 (ko) 2006-05-31 2012-03-07 에프. 호프만-라 로슈 아게 아릴-4-에틴일-아이속사졸 유도체
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
CN101965344B (zh) 2007-06-22 2013-03-06 弗·哈夫曼-拉罗切有限公司 异*唑-咪唑衍生物
US7618973B2 (en) 2007-12-04 2009-11-17 Hoffmann-La Roche Inc. Isoxazolo-pyrazine derivatives
JP5301557B2 (ja) 2007-12-04 2013-09-25 エフ．ホフマン−ラ ロシュ アーゲー イソオキサゾロ−ピリジン誘導体
EP2128158A1 (en) 2008-05-26 2009-12-02 Phenex Pharmaceuticals AG Heterocyclic cyclopropyl-substituted FXR binding compounds
US8389550B2 (en) 2009-02-25 2013-03-05 Hoffmann-La Roche Inc. Isoxazoles / O-pyridines with ethyl and ethenyl linker
US8222246B2 (en) 2009-04-02 2012-07-17 Hoffmann-La Roche Inc. Substituted isoxazoles
US8227461B2 (en) 2009-04-30 2012-07-24 Hoffmann-La Roche Inc. Isoxazoles
BRPI1013762A2 (pt) 2009-05-05 2015-08-25 Hoffmann La Roche "derivados isoxazol-piridazina"
BRPI1014454A2 (pt) 2009-05-05 2016-04-05 Hoffmann La Roche derivados de isoxazol-pirazol
US8415379B2 (en) 2009-05-05 2013-04-09 Hoffmann-La Roche Inc. Pyridines
ES2601181T3 (es) 2009-05-05 2017-02-14 F. Hoffmann-La Roche Ag Derivados de isoxazol-tiazol como agonistas inversos del receptor GABA A para su uso en el tratamiento de trastornos cognitivos
KR101354416B1 (ko) 2009-05-07 2014-02-19 에프. 호프만-라 로슈 아게 감마-아미노부티르산 조절제로서 이속사졸-피리딘 유도체
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
CN103189062B (zh) 2010-11-05 2016-03-23 霍夫曼-拉罗奇有限公司 活性药物化合物用于治疗中枢神经系统病症的用途
RU2582337C2 (ru) * 2010-11-09 2016-04-27 Ф.Хоффманн-Ля Рош Аг Производные триазола в качестве лигандов рецепторов гамк
JP2014122161A (ja) 2011-03-31 2014-07-03 Astellas Pharma Inc ピラゾール化合物
MX357504B (es) 2012-06-26 2018-07-12 Saniona Aps Derivado de feniltriazol y su uso para modular complejo del receptor gabaa.
MA48594B1 (fr) 2016-12-08 2022-05-31 Hoffmann La Roche Nouveaux dérivés d'éther d'isoxazolyle en tant que pam alpha5 gaba a

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011505402A (ja) 2007-12-04 2011-02-24 エフ．ホフマン−ラ ロシュ アーゲー イソオキサゾロ−ピリダジン誘導体
JP2013543852A (ja) 2010-11-09 2013-12-09 エフ．ホフマン−ラ ロシュ アーゲー トリアゾール誘導体及びその神経障害に対する使用
WO2014001278A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001280A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
JP2015521643A (ja) 2012-06-26 2015-07-30 サニオナ・エイピイエス フェニルトリアゾール誘導体及びｇａｂａａ受容体複合体を調節するための該フェニルトリアゾール誘導体の使用

Also Published As

Publication number Publication date
CN112424197A (zh) 2021-02-26
EP3823967A1 (en) 2021-05-26
TW202019915A (zh) 2020-06-01
BR102019014802A2 (pt) 2020-02-04
JP2021531291A (ja) 2021-11-18
US20200024261A1 (en) 2020-01-23
US20210147393A1 (en) 2021-05-20
WO2020016443A1 (en) 2020-01-23
AR117615A1 (es) 2021-08-18
CN112424197B (zh) 2025-04-22
US10941137B2 (en) 2021-03-09
EP3823967B1 (en) 2022-08-31

Similar Documents

Publication Publication Date Title
EP3823967B1 (en) Difluoromethyl-phenyl triazoles as gaba receptor modulators
AU2022202372B2 (en) Pyrimidin-2-ylamino-1H-pyrazols as LRRK2 inhibitors for use in the treatment of neurodegenerative disorders
JP2012507512A (ja) アミロイドβのモジュレーター
US10695334B2 (en) Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors
JP2025168356A (ja) ジフルオロメチル－ピリジン－２－イルトリアゾール
JPWO2007114323A1 (ja) アミノピロリジン化合物
JP2017514809A (ja) キノキサリン化合物及びその使用
CA2829171C (en) Pyrazolidin-3-one derivatives
CN116354937B (zh) 吡啶(嘧啶)胺类衍生物及其应用
DK3030561T3 (en) N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE
CA2999940A1 (en) Substituted morpholine derivatives having activity against pain
HK40129488A (en) Difluoromethyl-pyridin-2-yl triazoles
EP3971179A1 (en) Difluoromethyl-pyridin-2-yl triazoles
EP3950683A1 (en) Difluoromethyl-pyridin-2-yl triazoles
EP3992188A1 (en) Difluoromethyl-pyridin-2-yl triazoles

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220715

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230605

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230613

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230706

R150 Certificate of patent or registration of utility model

Ref document number: 7311583

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250